Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Finding and drugging the vulnerabilities of RAS-dependent cancers.

Sawyers CL.

Cell. 2009 May 29;137(5):796-8. doi: 10.1016/j.cell.2009.05.011.

2.

Using cells devoid of RAS proteins as tools for drug discovery.

Urosevic J, Sum EY, Moneo V, Drosten M, Dhawahir A, Becerra M, Carnero A, Barbacid M.

Mol Carcinog. 2009 Nov;48(11):1038-47. doi: 10.1002/mc.20555.

PMID:
19526460
3.

Therapeutic Approaches to RAS Mutation.

Scott AJ, Lieu CH, Messersmith WA.

Cancer J. 2016 May-Jun;22(3):165-74. doi: 10.1097/PPO.0000000000000187. Review.

4.

Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.

Calleros L, Sánchez-Hernández I, Baquero P, Toro MJ, Chiloeches A.

Carcinogenesis. 2009 Oct;30(10):1670-7. doi: 10.1093/carcin/bgp188. Epub 2009 Aug 20.

PMID:
19700418
5.

Ras signaling and therapies.

Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F.

Adv Cancer Res. 2009;102:1-17. doi: 10.1016/S0065-230X(09)02001-6. Review.

PMID:
19595305
6.

New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Mascarenhas CC, Cunha AF, Miranda EC, Zulli R, Silveira RA, Costa FF, Pagnano KB, De Souza CA.

Leuk Lymphoma. 2009 Jul;50(7):1148-54. doi: 10.1080/10428190902930496.

PMID:
19557636
7.

Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout.

Versele M, Talloen W, Rockx C, Geerts T, Janssen B, Lavrijssen T, King P, Göhlmann HW, Page M, Perera T.

Mol Cancer Ther. 2009 Jul;8(7):1846-55. doi: 10.1158/1535-7163.MCT-08-1029. Epub 2009 Jul 7.

8.

Farnesyltransferase inhibitor as anticancer agent.

Agrawal AG, Somani RR.

Mini Rev Med Chem. 2009 Jun;9(6):638-52. Review.

PMID:
19519490
9.

The era of targeted therapies.

Offermann M.

Am Fam Physician. 2008 Feb 1;77(3):294, 296. No abstract available.

10.
11.

Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.

Pappano WN, Jung PM, Meulbroek JA, Wang YC, Hubbard RD, Zhang Q, Grudzien MM, Soni NB, Johnson EF, Sheppard GS, Donawho C, Buchanan FG, Davidsen SK, Bell RL, Wang J.

BMC Cancer. 2009 Sep 4;9:314. doi: 10.1186/1471-2407-9-314.

12.

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.

Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.

13.

Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.

Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G, Torri V.

Anticancer Res. 2009 Jul;29(7):2691-701. Review.

14.

Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.

Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ, Parikh MD.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4882-4. doi: 10.1016/j.bmcl.2009.02.017. Epub 2009 Feb 8.

PMID:
19616942
15.

[Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].

Molven A, Søvik O, von der Lippe C, Steine SJ, Njølstad PR, Houge G, Prescott TE.

Tidsskr Nor Laegeforen. 2009 Nov 19;129(22):2358-61. doi: 10.4045/tidsskr.09.0267. Norwegian.

16.

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.

Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Markland W, Namchuk MN, Nanthakumar S, Poondru S, Straub J, ter Haar E, Xie X.

J Med Chem. 2009 Oct 22;52(20):6362-8. doi: 10.1021/jm900630q.

PMID:
19827834
17.

Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.

Cakir M, Grossman AB.

Expert Opin Ther Targets. 2009 Sep;13(9):1121-34. doi: 10.1517/14728220903170675. Review.

PMID:
19637976
18.

Novel targeted radiosensitisers in cancer treatment.

Zaidi SH, Huddart RA, Harrington KJ.

Curr Drug Discov Technol. 2009 Jun;6(2):103-34. Review.

PMID:
19519337
19.

The GTPase cycle. How dominant inhibitory mutants block the biological functions of small GTPases.

Manser EJ.

Methods Mol Biol. 2002;189:3-11. No abstract available.

PMID:
12094593
20.

Stops along the RAS pathway in human genetic disease.

Bentires-Alj M, Kontaridis MI, Neel BG.

Nat Med. 2006 Mar;12(3):283-5. No abstract available.

PMID:
16520774

Supplemental Content

Support Center